Biomira sinks in as drug trial misses endpoints 17.06.2003 13:41 Headlines
Biomira shares are sinking $1.10, or 28 percent, to $2.90 in Instinet
pre-open trading after the company reported results from a Phase III trial of
its vaccine for women with breast cancer, Theratope, that did not meet the
primary endpoints of time to disease progression and overall survival. The
company said it would determine how to proceed with Theratope following
discussions with regulatory agencies regarding the trial results. The company
noted that it would continue the other clinical trials of Theratope that were
currently underway.
This story was supplied by CBSMarketWatch. For further information see
www.cbsmarketwatch.com.
Biomira shares are sinking $1.10, or 28 percent, to $2.90 in Instinet
pre-open trading after the company reported results from a Phase III trial of
its vaccine for women with breast cancer, Theratope, that did not meet the
primary endpoints of time to disease progression and overall survival. The
company said it would determine how to proceed with Theratope following
discussions with regulatory agencies regarding the trial results. The company
noted that it would continue the other clinical trials of Theratope that were
currently underway.
This story was supplied by CBSMarketWatch. For further information see
www.cbsmarketwatch.com.
